Pathfinder Cell Therapy Inc (PFND)

0.00 USD  |  OTCM  |  Jun 17, 16:00
More

Price Chart

Key Stats

View All Stats
Price and Performance
Market Cap 0.00
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
All-Time High (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Month Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) --
Valuation
PE Ratio --
PE Ratio (Forward) Upgrade
PS Ratio --
Price to Book Value --
EV to EBITDA Upgrade
Dividend
Dividend --
Dividend Yield (Forward) Upgrade
Financials
Revenue (5 Year Growth) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (5 Year Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
Debt to Equity Ratio --
Return on Equity Upgrade
Return on Assets Upgrade
Risk
Beta (5Y) Upgrade
Max Drawdown (5Y) 100.00%

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (“PCs”) themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
URL http://www.pathfindercelltherapy.com
Investor Relations URL N/A
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (“PCs”) themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
URL http://www.pathfindercelltherapy.com
Investor Relations URL N/A
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A